Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 in Progressive Multiple Sclerosis
NCT05054140Phase 2Active, not recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing IMU-838 with Placebo (2 arms). Primary endpoint: Annualized rate of percent brain volume change at 120 weeks. Started Sep 2021; status: active, not recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05054140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054140.